{
  "id": 1516242,
  "title": "Common arthritis pill repurposed to boost hair regrowth in alopecia patients",
  "url": "https://urgent.news/2026/08/17/common-arthritis-pill-repurposed-to-boost-hair-regrowth-in-alopecia",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-17T16:40:01.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-08-common-arthritis-pill-repurposed-boost.html"
  },
  "original_language": "en",
  "account": "Upadacitinib, a medication commonly used to treat rheumatoid arthritis, has been repurposed to help boost hair regrowth in patients with alopecia areata, a condition causing patchy hair loss. Two recent Phase III trials involving over 1,400 people showed that the drug significantly increased hair regrowth compared to a placebo. In the 24-week period, nearly half of those taking 15 mg daily reached 80% scalp hair coverage, while 54% of those on 30 mg daily achieved the same result. The effect extended beyond the scalp, with notable improvements in eyebrows and eyelashes. Adults and adolescents with severe alopecia who took upadacitinib experienced substantially more hair regrowth than those on placebo. The drug's side effects were generally mild, with acne and respiratory infections being the most common. This repurposed use of upadacitinib offers a promising treatment option for those suffering from severe alopecia areata, potentially restoring confidence and quality of life for millions affected by the condition.",
  "summary": "Upadacitinib is a medication widely used for the treatment of rheumatoid arthritis that works by inhibiting Janus kinase (JAK) enzymes, which are involved in signaling pathways that regulate immune responses. Now, scientists have found another application for this immune system-modulating drug. Two recent Phase III international trials involving 1,399 people found that upadacitinib helped with…",
  "key_points": [
    "Upadacitinib, arthritis pill, repurposed for hair regrowth",
    "Phase III trials with 1,400+ participants show significant results",
    "80% scalp hair coverage in 24 weeks for 15 mg daily dose"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}